To evaluate and compare changes in healthcare resource utilization and costs associated with the initiation of pregabalin or gabapentin in pDPN patients in a real-world setting. METHODS: A retrospective cohort study utilizing the MarketScan Commercial Claims and Encounters Database (2007Database ( -2009. Patients with a new prescription for pregabalin or gabapentin in 2008 (date of the prescription defined as index date) and Ն1 healthcare encounter with an ICD-9 code for diabetic peripheral neuropathy (DPN; 250.6 or 357.2) within 30 days prior to the first prescription for pregabalin or gabapentin were identified and propensity score matched. Both cohorts were continuously enrolled for the 12 month pre-and postindex periods during which health care utilization and costs were assessed. Pre-to post-index changes were compared between pregabalin and gabapentin using a difference-in-difference (DID) approach. RESULTS: 910 pregabalin patients (48.6% female; mean age 63.3Ϯ12.1 years) were matched to 910 gabapentin patients (48.8% female; mean age 63.3Ϯ12.1 years); other demographic and clinical characteristics were also comparable between cohorts, with the exception of US region. The pre-to post-index DID in resource utilization did not differ between the two cohorts including: number of office visits per patient (Pϭ0.66), number of ER visits (Pϭ0.78), number of inpatient stays (Pϭ0.92), average inpatient length of stay per hospitalization (Pϭ0.79), number of total prescriptions filled (Pϭ0.37). The DID of total healthcare costs per patient were non-significant with pre-to post-index increases of $3,081 in pregabalin patients and $4,683 in gabapentin patients (Pϭ0.50). CONCLUSIONS: Patients with pDPN initiating pregabalin or gabapentin experienced comparable changes in healthcare resource utilization and costs. These results suggest overall cost neutrality between pregabalin and gabapentin.
OBJECTIVES:
To identify the factors associated with high healthcare expenditure among obese individuals in the United States. METHODS: Analytical sample consisted of obese adults 20 years or older with (BMIՆ30). Total yearly expenditures for obese adults were obtained from 2007 Medical Expenditure Panel Survey data. Observations with total yearly healthcare expenditure greater than 90 th percentile were classified as high healthcare expenders and coded yes/no to be used as the dependent variable. Independent factors selected according to the Anderson's Behavioral Model were age, gender, race, MSA, region, education, poverty category, source of payment, usual source of care, MSA, education, general health status, mental health status and mortality risk status. 'Surveylogistic' regression was used to determine the predictors of high expenditures. RESULTS: Descriptive analysis show that adults with high healthcare expenditure were whites (74.23%), had midschool education (60%), lived in MSA (79%), had usual care provider (95%), private insurance (67%) and belonged to very high mortality risk group (46%). In adjusted analysis, age (OR: 1.019 CI: 1.009-1.029), usual source of care (OR: 1.901 CI: 1.196-3.020), private (OR: 3.609 CI: 1.992-6.539) and public insurance (OR: 3.251 CI: 1.781-5.936), very high (OR: 3.342 CI: 2.327-4.798) and high (OR: 2.213 CI: 1.666-2.938) mortality risk and general health status (OR: 2.493 CI: 2.148-2.893) were associated with high healthcare expenditure. CONCLUSIONS: Several enabling and need factors seem to be associated with high healthcare expenditure. Both private and public health insurance have a significant burden of healthcare expenditure associated with obesity. Individuals with usual source of care are more likely to incur high healthcare expenditure. Comorbidities have a significant impact on healthcare expenditure among obese individuals and highlight the need to deliver comprehensive disease state management. The findings from this study can have important implications in understanding increased utilization of health services among obese adults in the United States.
PSY29 A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND OXYMORPHONE LONG-ACTING ORAL TABLETS
Rubino M 1 , Summers KH 1 , Ohsfeldt R 2 , Ben-Joseph R 1 , Puenpatom RA 1 1 Endo Pharmaceuticals, Inc., Chadds Ford, PA, USA, 2 Texas A&M Health Science Center, College Station, TX, USA OBJECTIVES: Although both oxycodone CR and oxymorphone ER are approved for twice daily dosing, it is unclear whether actual utilization is consistent with this. The objective was to assess whether there exist differences in the utilization of oxycodone CR and oxymorphone ER. METHODS: We used prescription claims data from a commercially-insured population (i3 InVision Data Mart database), during the period January 1, 2007 to March 31, 2010. A claim for at least one 30-day supply of study drug one month prior to the observation period was necessary to avoid capturing utilization associated with titration. Subsequently, all subjects had a claim for at least a 90-day supply of the respective opioid analgesic. Patients' claims were excluded from this analysis if there was evidence of a switch from one to the other study opioid during the 90-day observation period. There were no limitations on the use of other opioids, during the baseline or observation periods. The final cohort consisted of 6,567 oxycodone CR patients and 796 oxymorphone ER patients. In addition to univariate analysis, multivariate analyses were conducted using generalized linear models (GLM) to adjust for the observed heterogeneity among patients in the observational database. RESULTS: The unadjusted daily average supply (DASUP) mean values for the highest strengths of oxycodone CR (80 mg) was 3.9 compared to 2.9 for oxymorphone ER (40mg), 3.0 vs. 2.4 for all lower strengths, and 3.1 vs. 2.5 for all strengths. (all pϽ0.001). After adjusting for baseline differences, a risk-adjusted overall mean difference in DASUP remained with oxycodone CR patients receiving, on average, 0.6 tablets more per day than those dispensed oxymorphone ER (pϽ0.001). The direction, magnitude and statistical significance of these differences were essentially unchanged in sensitivity analyses. CONCLUSIONS: In managing the pharmacy benefit, decision-makers may want to consider the financial implications of these DASUP differences.
Systemic Disorders/Conditions -Patient-Reported Outcomes & Preference-Based Studies PSY30 A REAL-WORLD EVALUATION OF ADHERENCE AND PERSISTENCE OF WEIGHT-LOSS PHARMACOTHERAPY IN THE UNITED STATES: 2007-2010
Charland SL, Agatep BC, Aubert RE, Lazzaro J, Stanek EJ Medco Research Institute, Medco Health Solutions, Inc, Bethesda, MD, USA OBJECTIVES: There is a rapidly growing overweight and obesity epidemic in the US, and a high demand for long-term safe and effective weight-loss agents. While 3 new antiobesity therapies underwent FDA review in 2010, little is known about the utilization of available weight-loss drugs. The objective of this analysis is to describe the real-world prescription patterns, adherence, and persistence of weightloss pharmacotherapy in the United States. METHODS: A retrospective cohort analysis was conducted using Medco's integrated claims database to evaluate adult patients initiating weight-loss pharmacotherapy between May 2007-October 2010. Eligibility criteria included new weight-loss drug prescription claims (no weight-loss therapy prescriptions 6 months prior to index claim date) and continuous eligibility for 6 months pre-and 14 months post-index claim date. Patients on drugs with Ͼ1000 distinct patient counts were analyzed for adherence (annual Medication Possession Ratio; MPR), persistency (allowing a 45 day gap), and concomitant therapy. RESULTS: Analyses included 91,160 patients receiving five drugs: phentermine (Nϭ67434), sibutramine (Nϭ13438), orlistat (Nϭ8047), phendimetrazine (Nϭ4631), and, diethylpropion (Nϭ 4350). MeanϮSD age was 44Ϯ12 years (96%, 18-64 y/o), 82% were female, 46% resided in the South, and 91% filled prescriptions at retail only. Among obesity drug prescribers with known specialty, 71% were family/internal medicine practitioners. Patients received a mean of 3Ϯ3 concomitant chronic medications, with 38%, 31%, 22%, and 11% on antihypertensive, antidepressant, dyslipidemia, or oral antidiabetic therapy, respectively. The mean adherence ranged from MPRϭ0.20 (phendimetrazine) to MPRϭ0.26 (phentermine). Persistence at 3, 6, and 12 months ranged respectively from 26%-38% (lowphendimetrazine, high-phentermine), 9%-16% (low-phendimetrazine, high-sibutramine), and 3%-6% (low-phendimetrazine, high-sibutramine). CONCLUSIONS: Weight-loss pharmacotherapies in the United States were prescribed by primary care physicians to predominantly younger, female patients on concomitant therapy for common obesity-related conditions. Adherence and persistence to therapy is low, even over short-term exposure, although treatment duration may extend beyond recommendations in some cases (e.g., phentermine).
PSY31 HEMOPHILIA A: PATIENT IMPACT AND ECONOMIC BURDEN OF THE DISEASE
Strandberg-Larsen M 1 , Gater A 2 , Thomson A 2 1 Novo Nordisk, Inc., Søborg, Denmark, 2 MAPI Values, Bollington, Cheshire, UK OBJECTIVES: Hemophilia A is a rare but serious bleeding disorder caused by a blood clotting factor VIII (FVIII) deficiency. To examine the impact of hemophilia A and replacement FVIII therapies from a humanistic and economic perspective, a targeted literature review was conducted. METHODS: Searches were conducted in MEDLINE ® and the National Health Service Economic Evaluation Database, using disease, patient-reported outcome and economic-related key words, limited to English articles published from January 2000-January 2010 (inclusive). From 653 abstracts retrieved, 34 full-text articles were selected for detailed consideration. RESULTS: Findings revealed increased mortality rates and decreased life expectancy among people with hemophilia A, compared with the general population. This is largely attributed to the transmission of blood-borne viruses (e.g. HIV and Hepatitis-C) due to use of plasma-derived FVIII (pdFVIII) concentrates. Improvements in viral attenuation processes plus donor screening practices for pdFVIII products have reduced the risks of viral transmission, but risk from non-enveloped viruses and other unknown pathogens still exists. Newly developed recombinant FVIII therapies minimize these risks; however, such therapies are not currently widely available globally. All available FVIII therapies use demanding regimens requiring regular time-consuming injections, which can be detrimental to patients' health-related quality of life and limit adherence. Non-adherence is associated with diminished product efficacy, poorer health outcomes and increasing economic expenditure. Treating hemophilia A is costly, primarily due to the high acquisition cost of replacement FVIII products. However, indirect costs (e.g. patient disability) also contribute to economic burden. Prophylactic treatment, while ini-tially more expensive than on-demand treatment, is associated with greater clinical efficacy and improved long-term outcomes, which may lead to cost savings over a patient's lifetime. CONCLUSIONS: Hemophilia A is associated with considerable humanistic and economic burden. Substantial unmet needs remain among hemophilia A patients with regard to the safety, convenience and global access to FVIII therapy.
PSY32 HOW DO MINIMALLY IMPORTANT DIFFERENCES VALUE OUTCOMES?
Suh JK, Doctor J USC School of Pharmacy, Los Angeles, CA, USA OBJECTIVES: To assess the functional form of the minimally important difference (MID) METHODS: Subjects were shown a base body weight, y1, and a current body weight after a treatment, y2. If a subject endorsed y2 as an important difference over y1, we denoted a pair (y2, y1). An MID is the y1 and y2 difference when the probability of discriminating y2 from y1 was greater than 0.5. The standard formula of this discrimination probability is given by Fechner's Law: P(y2, y1) ϭ F(U(y2) -U(y1)) where F is an increasing function and U is a MID function. When the probability of discrimination is constant over proportional changes in weight (i.e., Weber's Law: P(y2, y1) ϭ P(␣y2, ␣y1)), the utility function for health states is a log function. To assess the functional form of U, we tested a hypothesis of P(y2, y1) ϭ P(␣y2, ␣y1) ϭ 0.5. An on-line survey was conducted with three base weights: 29, 36, and 43 lb overweight. One-way repeated measure analysis of variance (Wilk's test) and one-way within subjects analysis were used. RESULTS: A total of 131 subjects participated. The mean MID values were 9.391 (SD ϭ 4.001), 11.195 (SDϭ 5.236), and 13.073 (SD ϭ 6.491) for 29, 36, and 43 lb overweight, respectively. The normalized mean MID values were 0.323 (SD ϭ 0.138), 0.311 (SDϭ 0.145), and 0.304 (SD ϭ 0.151) for 29, 36, and 43 lb overweight, respectively. The results of Wilk's test was not statistically significant (p ϭ 0.2807) Moreover, one-way within subjects resulted in no effect of the different body weights on the MIDs at the significance level ␣ϭ0.01. CONCLUSIONS: The normalized mean MIDs from three different body weights were not statistically different. Within the limited range studied MIDs fit a log utility model. Thus, MIDs may be problematic as a prescriptive policy tool.
PSY33 EXPLORING THE FACTOR STRUCTURE OF THE PROMIS FATIGUE ITEM BANK IN PATIENTS WITH FIBROMYALGIA
Schilling S 1 , Blum SI 2 , Tourkodimitris S 2 , Williams DA 1 1 University of Michigan, Ann Arbor, MI, USA, 2 Forest Research Institute, Jersey City, NJ, USA OBJECTIVES: The NIH roadmap project "Patient-Reported Outcomes Measurement Information System" (PROMIS) provides a basis for measuring symptoms -including fatigue; associated with chronic diseases. However, information on use of PRO-MIS with Fibromyalgia (FM) patients is limited. This study sought to evaluate the factor structure of the 95-item PROMIS Fatigue item bank among individuals with FM. It is unknown whether the conceptual structure of fatigue experience (intensity, frequency, and duration) and impact (physical and mental) will be supported in individuals with FM. METHODS: An internet-based survey was conducted with individuals with FM. Participants had to be Ն18 years and diagnosed with FM by a physician. Respondents were randomized into one of three cohorts, each of which completed one-third of the 95-items from the entire PROMIS v1.0 Fatigue Item Bank (www.nihpromis.org). Items were balanced between cohorts. Item factor analysis was performed using both a polychoric correlation matrix with Mplus and a fullinformation approach using ORDFAC. Comparisons were made using the Akaike Information Criteria (AIC) and Bayesian Information Criterion (BIC). Models chosen based on BIC produced interpretable factors for assessment of the PROMAX rotated factor loadings. RESULTS: 1,207 respondents completed the survey. Mean age of the respondents was 52.1 years. Mean time since FM diagnosis was 8.7 years. All groups produced factor structures that included 3 factors. The first consisted mainly of Fatigue Experience items. The second consisted mainly of items related to Mental Impact and the third consisted of General Impact items. An additional factor related to Social Impact was identified in Group B only. CONCLUSIONS: For individuals with FM, the PROMIS Fatigue item bank appears to contain a factor structure that is consistent with the original PROMIS conceptual model. Subscales from the PROMIS Fatigue item bank can likely be used to separate Fatigue Experience from General and Mental impacts of Fatigue.
PSY34 CALCULATING PROMIS FATIGUE ITEM BANK IRT PARAMETER ESTIMATES SPECIFIC TO PATIENTS WITH FIBROMYALGIA
Schilling S 1 , Blum SI 2 , Tourkodimitris S 2 , Williams DA 1 1 University of Michigan, Ann Arbor, MI, USA, 2 Forest Research Institute, Jersey City, NJ, USA OBJECTIVES: The NIH roadmap project "Patient-Reported Outcomes Measurement Information System" (PROMIS) provides a basis for measuring symptoms -including fatigue; associated with chronic diseases. However, information on use of PROMIS with Fibromyalgia (FM) patients is limited. This study sought to re-estimate the Item Response Theory (IRT) item parameter estimates for each of the 95-items included in the PROMIS Fatigue item bank using responses from individuals with FM. It is unknown whether the parameter estimates differ among a sample of FM patients from that of the broader population used in the initial PROMIS item calibrations. METHODS: An internet-based survey was conducted with individuals with FM. Participants had to be Ն18 years and diagnosed with FM by a physician. Respondents were randomized into one of three cohorts, each of which completed one-third of the 95-items from the entire PROMIS v1.0 Fatigue Item Bank (www.nihpromis.org). IRT model fitting of Samejima's Graded Response Model (GRM) was conducted using MULTILOG7 to determine item parameter estimates and compared with standard PROMIS parameter estimates. RESULTS: A total of 1,207 re-spondents completed the survey. IRT item parameter estimates (slope and item characteristic curve thresholds) and item information functions were obtained for all 95-items. Mean score across all items for the FM sample was 3.68 compared to the PROMIS mean of 2.12. Maximum information function was Ͼ2 for 22/95 items in the FM sample, compared to only 2/95 items in the PROMIS sample, indicating differences in both discriminate ability as well as the difficulty of items for a FM specific population. CONCLUSIONS: Disease specific item level calibrations of PRO-MIS items can be estimated. Using the same GRM methodology as PROMIS we were able to calculate revised item parameter estimates and information functions. These estimates can be used to construct improved efficient short-forms or for application in computer adaptive testing.
